Olympus Corporation

PINK:OLYMY USA Medical Devices
Market Cap
$13.36 Billion
Market Cap Rank
#1537 Global
#1157 in USA
Share Price
$12.13
Change (1 day)
-2.10%
52-Week Range
$12.13 - $13.53
All Time High
$19.30
About

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting… Read more

Olympus Corporation (OLYMY) - Net Assets

Latest net assets as of September 2025: $733.58 Billion USD

Based on the latest financial reports, Olympus Corporation (OLYMY) has net assets worth $733.58 Billion USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.38 Trillion) and total liabilities ($651.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $733.58 Billion
% of Total Assets 52.97%
Annual Growth Rate 5.67%
5-Year Change 90.08%
10-Year Change 95.62%
Growth Volatility 55.44

Olympus Corporation - Net Assets Trend (2003–2025)

This chart illustrates how Olympus Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Olympus Corporation (2003–2025)

The table below shows the annual net assets of Olympus Corporation from 2003 to 2025.

Year Net Assets Change
2025-03-31 $751.73 Billion -0.72%
2024-03-31 $757.19 Billion +18.08%
2023-03-31 $641.23 Billion +25.40%
2022-03-31 $511.36 Billion +29.30%
2021-03-31 $395.48 Billion +6.32%
2020-03-31 $371.96 Billion -15.92%
2019-03-31 $442.39 Billion -0.42%
2018-03-31 $444.26 Billion +3.11%
2017-03-31 $430.88 Billion +12.13%
2016-03-31 $384.28 Billion +7.57%
2015-03-31 $357.25 Billion +7.84%
2014-03-31 $331.28 Billion +117.37%
2013-03-31 $152.41 Billion +217.33%
2012-03-31 $48.03 Billion -71.21%
2011-03-31 $166.84 Billion -23.08%
2010-03-31 $216.89 Billion +28.50%
2009-03-31 $168.78 Billion -54.12%
2008-03-31 $367.88 Billion +6.67%
2007-03-31 $344.87 Billion +14.84%
2006-03-31 $300.31 Billion +18.18%
2005-03-31 $254.12 Billion +0.31%
2004-03-31 $253.34 Billion +13.45%
2003-03-31 $223.31 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Olympus Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 251.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings $420.97 Billion 56.00%
Other Components $330.77 Billion 44.00%
Total Equity $751.73 Billion 100.00%

Olympus Corporation Competitors by Market Cap

The table below lists competitors of Olympus Corporation ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Olympus Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 757,186,000,000 to 751,733,000,000, a change of -5,453,000,000 (-0.7%).
  • Net income of 117,855,000,000 contributed positively to equity growth.
  • Dividend payments of 20,981,000,000 reduced retained earnings.
  • Share repurchases of 100,002,000,000 reduced equity.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $117.86 Billion +15.68%
Dividends Paid $20.98 Billion -2.79%
Share Repurchases $100.00 Billion -13.3%
Other Changes $-2.33 Billion -0.31%
Total Change $- -0.72%

Book Value vs Market Value Analysis

This analysis compares Olympus Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.02x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-03-31 $209.84 $12.13 x
2004-03-31 $238.47 $12.13 x
2005-03-31 $228.99 $12.13 x
2006-03-31 $269.63 $12.13 x
2007-03-31 $309.03 $12.13 x
2008-03-31 $329.56 $12.13 x
2009-03-31 $150.37 $12.13 x
2010-03-31 $194.27 $12.13 x
2011-03-31 $152.36 $12.13 x
2012-03-31 $41.94 $12.13 x
2013-03-31 $134.59 $12.13 x
2014-03-31 $248.19 $12.13 x
2015-03-31 $259.85 $12.13 x
2016-03-31 $279.53 $12.13 x
2017-03-31 $313.52 $12.13 x
2018-03-31 $323.50 $12.13 x
2019-03-31 $322.91 $12.13 x
2020-03-31 $282.40 $12.13 x
2021-03-31 $306.58 $12.13 x
2022-03-31 $397.45 $12.13 x
2023-03-31 $510.62 $12.13 x
2024-03-31 $622.57 $12.13 x
2025-03-31 $655.71 $12.13 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Olympus Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 15.68%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 11.82%
  • • Asset Turnover: 0.70x
  • • Equity Multiplier: 1.91x
  • Recent ROE (15.68%) is above the historical average (3.17%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 10.95% 4.31% 0.93x 2.72x $2.10 Billion
2004 13.31% 5.30% 0.93x 2.71x $8.35 Billion
2005 -4.91% -1.45% 0.95x 3.56x $-35.91 Billion
2006 9.83% 2.92% 1.00x 3.36x $-501.60 Million
2007 14.30% 4.50% 0.97x 3.27x $14.38 Billion
2008 16.27% 5.14% 0.83x 3.81x $22.33 Billion
2009 -71.15% -11.71% 0.89x 6.86x $-130.95 Billion
2010 22.81% 5.41% 0.77x 5.50x $26.82 Billion
2011 4.51% 0.87% 0.80x 6.50x $-8.99 Billion
2012 -109.41% -5.77% 0.88x 21.59x $-53.46 Billion
2013 5.38% 1.08% 0.77x 6.44x $-6.89 Billion
2014 4.13% 1.91% 0.69x 3.12x $-19.34 Billion
2015 -2.46% -1.14% 0.71x 3.04x $-44.31 Billion
2016 16.35% 7.78% 0.80x 2.61x $24.32 Billion
2017 18.21% 10.45% 0.75x 2.31x $35.25 Billion
2018 12.89% 7.26% 0.80x 2.21x $12.78 Billion
2019 1.85% 1.03% 0.85x 2.11x $-35.97 Billion
2020 13.94% 6.48% 0.79x 2.74x $14.60 Billion
2021 3.28% 1.72% 0.64x 3.00x $-26.51 Billion
2022 22.73% 13.15% 0.65x 2.66x $64.95 Billion
2023 22.41% 16.26% 0.58x 2.36x $79.42 Billion
2024 32.04% 26.20% 0.60x 2.03x $166.85 Billion
2025 15.68% 11.82% 0.70x 1.91x $42.68 Billion

Industry Comparison

This section compares Olympus Corporation's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $539,803,485
  • Average return on equity (ROE) among peers: -52.41%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Olympus Corporation (OLYMY) $733.58 Billion 10.95% 0.89x $11.25 Billion
Advanced Biomedical Technologies Inc (ABMT) $-7.40 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $3.67 Billion 38.07% 1.09x $190.05 Billion
Acarix AB (publ) (ACIXF) $1.44 Million -102.09% 0.28x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-13.54K 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $2.76 Million -21.69% 0.89x $3.17 Million
Aethlon Medical Inc (AEMD) $9.28 Million -68.70% 0.12x $2.76 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $1.58 Billion 5.73% 1.84x $911.62 Million
Allied Healthcare Products Inc. (AHPIQ) $11.89 Million -17.74% 0.30x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $456.18K -277.12% 2.12x $10.62 Million